Accueil・Liste d'Actions・Organon & Co

Organon & Co

Fermé

SecteurSoins de santé

13.75 -0.15

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.77

Max

13.77

Chiffres clés
By Trading Economics
Revenu	-292M -146M
Ventes	98M 1.6B
P/E Moyenne du Secteur	17.641 56.659
BPA	0.8
Rendement du dividende	0.58
Marge bénéficiaire	-9.355
Employés	10,000
EBITDA	-38M 371M

Dividendes
By Acuity
Rendement du dividende Moyenne du Secteur	0.58% 2.18%
Prochains Résultats	9 nov. 2026
Date du Prochain Dividende	10 sept. 2026
Date du Prochain Détachement de Dividende	19 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	63M 3.6B
Ouverture précédente	13.9
Clôture précédente	13.75

Sentiment de l'Actualité

By Acuity

16%

84%

20 / 339 Classement par Healthcare

Organon & Co Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 sept. 2026, 20:08 UTC

Organon & Co. shares are trading roughly flat, showing little change since Tuesday's close, amid stability near the upper end of their one-month range.

1 sept. 2026, 23:01 UTC

Organon & Co. shares are lower in after-market trading, continuing a downward trend amid broader market unease over economic data indicating a growth slowdown.

28 août 2026, 19:26 UTC

Organon & Co. shares are trading roughly flat, with no specific news identified. The stock remains near the upper end of its one-month trading range.

27 août 2026, 23:01 UTC

Shares of Organon & Co. traded lower in after-market hours, continuing a decline observed earlier in the session without any specific company news identified.

25 août 2026, 19:36 UTC

Organon & Co. shares are near unchanged, trading within a narrow range with no specific news identified during Tuesday's session.

24 août 2026, 23:02 UTC

Organon & Co shares are trading lower in after-market hours. Broader geopolitical tensions, particularly the U.S.-Iran situation, may be influencing market sentiment.

21 août 2026, 23:41 UTC

Organon & Co. shares are lower in after-hours trading, following a decline from earlier highs and reaching a session low. No specific news was identified.

20 août 2026, 22:01 UTC

Organon & Co shares are trading lower in after-market hours, continuing a downward trend since Thursday's close without any specific news to explain the movement.

19 août 2026, 23:01 UTC

Organon & Co shares declined in after-hours trading, reflecting unusual weakness since Wednesday's close. The stock is near the lower end of its one-month range.

18 août 2026, 23:51 UTC

Organon & Co shares are higher in after-market trading, reaching a maximum cumulative return shortly after Tuesday's close. No specific news was identified.

14 août 2026, 19:26 UTC

Organon & Co. shares are trading roughly flat, remaining above their 20-day moving average and near the upper end of their one-month range.

13 août 2026, 23:11 UTC

Organon & Co. shares are trading lower in after-market hours, despite an initial uptick, and remain near the upper end of their one-month trading range.

7 août 2026, 20:06 UTC

Shares of Organon & Co. are higher today, continuing a trend since Thursday's close amid a broader market increase. No specific company news was identified.

6 août 2026, 23:11 UTC

Shares of Organon & Co. are trading lower in after-market hours, reflecting routine action within its one-month trading range. No specific news was identified.

Comparaison

Variation de prix

Organon & Co prévision

Note du Consensus

By TipRanks

0 ratings

Achat

Maintien

Vente

Basé sur 0 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

20 / 339Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.